Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy DOI Open Access

Kyeonghee Shim,

Hyein Jo,

Dooil Jeoung

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(19), P. 14679 - 14679

Published: Sept. 28, 2023

In the last few decades, RNA-based drugs have emerged as a promising candidate in treatment of various diseases. The introduction messenger RNA (mRNA) vaccine or therapeutic agent enables production almost any functional protein/peptide. key to applying therapy clinical trials is developing safe and effective delivery systems. Exosomes lipid nanoparticles (LNPs) been exploited vehicles for drug delivery. This review discusses feasibility exosomes LNPs mRNA Cancer/testis antigens (CTAs) show restricted expression normal tissues widespread cancer tissues. Many these CTAs sera patients with cancers. These characteristics make them excellent targets immunotherapy. summarizes roles life processes current studies on mRNAs encoding CTAs. Clinical present beneficial effects highlight employing mRNA-LNPs

Language: Английский

Role of LncRNA H19 in tumor progression and treatment DOI Creative Commons
Linjing Li, Yuting Gao, Boyi Yu

et al.

Molecular and Cellular Probes, Journal Year: 2024, Volume and Issue: 75, P. 101961 - 101961

Published: April 8, 2024

As one of the earliest discovered lncRNA molecules, H19 is usually expressed in large quantities during embryonic development and involved cell differentiation tissue formation. In recent years, role tumors has been gradually recognized. Increasing evidence suggests that its aberrant expression closely related to cancer development. LncRNA as an oncogene not only promotes growth, proliferation, invasion metastasis many tumors, but also develops resistance treatment, affecting patients' prognosis survival. Therefore, this review, we summarise extensive research on involvement tumor progression discuss how H19, a key target gene, affects sensitivity radiotherapy, chemotherapy immunotherapy by participating multiple cellular processes regulating signaling pathways, which provides promising prospect for further into treatment cancer.

Language: Английский

Citations

7
Non-coding RNAs in thoracic disease: Barrett’s esophagus and esophageal adenocarcinoma DOI

Siyuan Sheng,

Jianhui Guo,

Chuangang Lu

et al.

Clinica Chimica Acta, Journal Year: 2025, Volume and Issue: unknown, P. 120242 - 120242

Published: March 1, 2025

Language: Английский

Citations

0
Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy DOI Open Access

Kyeonghee Shim,

Hyein Jo,

Dooil Jeoung

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(19), P. 14679 - 14679

Published: Sept. 28, 2023

In the last few decades, RNA-based drugs have emerged as a promising candidate in treatment of various diseases. The introduction messenger RNA (mRNA) vaccine or therapeutic agent enables production almost any functional protein/peptide. key to applying therapy clinical trials is developing safe and effective delivery systems. Exosomes lipid nanoparticles (LNPs) been exploited vehicles for drug delivery. This review discusses feasibility exosomes LNPs mRNA Cancer/testis antigens (CTAs) show restricted expression normal tissues widespread cancer tissues. Many these CTAs sera patients with cancers. These characteristics make them excellent targets immunotherapy. summarizes roles life processes current studies on mRNAs encoding CTAs. Clinical present beneficial effects highlight employing mRNA-LNPs

Language: Английский

Citations

4